{"id":"pembrolizumab-sintilimab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"3-5","effect":"Immune-related pneumonitis"},{"rate":"2-5","effect":"Immune-related hepatitis"},{"rate":"2-4","effect":"Immune-related colitis"},{"rate":"10-15","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These monoclonal antibodies bind to programmed death receptor-1 (PD-1) on the surface of T lymphocytes, preventing engagement with ligands PD-L1 and PD-L2 expressed by tumor cells and immune cells in the tumor microenvironment. By blocking this inhibitory checkpoint, the drugs restore T cell proliferation, activation, and cytotoxic function, enabling the immune system to recognize and eliminate cancer cells. This mechanism is particularly effective in tumors with high PD-L1 expression.","oneSentence":"Pembrolizumab and Sintilimab are PD-1 inhibitors that block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:22.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"},{"name":"Head and neck squamous cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07417501","phase":"PHASE2","title":"Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-03-01","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT06581497","phase":"","title":"ICIs With and Without MWA in Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"The First People's Hospital of Neijiang","startDate":"2022-01-01","conditions":"HCC, Therapy Adverse Effect","enrollment":52},{"nctId":"NCT07277777","phase":"PHASE2","title":"125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Malignant Tumors","enrollment":90},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07190027","phase":"PHASE1, PHASE2","title":"Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-11","conditions":"Advanced Non-Small Cell Lung Cancer (NSCLC)","enrollment":246},{"nctId":"NCT07100405","phase":"","title":"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT07067450","phase":"NA","title":"Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-07-20","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":98},{"nctId":"NCT07035860","phase":"","title":"Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2025-06-16","conditions":"Carbon Ion Radiotheray","enrollment":34},{"nctId":"NCT06728657","phase":"PHASE2","title":"Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma","status":"SUSPENDED","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer","enrollment":68},{"nctId":"NCT07010393","phase":"PHASE4","title":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-07-01","conditions":"Thyroid Neoplasms","enrollment":335},{"nctId":"NCT06991907","phase":"NA","title":"PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety","status":"COMPLETED","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2020-01-01","conditions":"HCC - Hepatocellular Carcinoma, 125I Seeds Implantation","enrollment":80},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT05549037","phase":"PHASE3","title":"Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2022-09-23","conditions":"Non-small Cell Lung Cancer","enrollment":210},{"nctId":"NCT06748508","phase":"PHASE2","title":"Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-12-25","conditions":"Gastric (Stomach) Cancer","enrollment":141},{"nctId":"NCT06734533","phase":"","title":"Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-12-05","conditions":"HR+ Breast Cancer","enrollment":80},{"nctId":"NCT06702566","phase":"NA","title":"The Effect of Serum Ferritin in irAE","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-04","conditions":"Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia","enrollment":1500},{"nctId":"NCT05979818","phase":"PHASE1","title":"Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-11-13","conditions":"Non Small Cell Lung Cancer, Propranolol","enrollment":6},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT06632106","phase":"","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2024-08-16","conditions":"Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor, Immune Checkpoint Inhibitors","enrollment":97},{"nctId":"NCT04770207","phase":"PHASE2","title":"Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma, Solid Tumor, Adult","enrollment":100},{"nctId":"NCT06549855","phase":"NA","title":"PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10","conditions":"Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency","enrollment":10},{"nctId":"NCT06502080","phase":"PHASE2","title":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07","conditions":"Biliary Tract Cancer","enrollment":128},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT04322617","phase":"PHASE2, PHASE3","title":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-03-24","conditions":"Non-small Cell Lung Cancer","enrollment":1200},{"nctId":"NCT05540145","phase":"","title":"Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-05-01","conditions":"Gastric Cancer","enrollment":70},{"nctId":"NCT06032052","phase":"PHASE2","title":"Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-02-01","conditions":"Elderly Patients, Metastatic Lung Cancer","enrollment":49},{"nctId":"NCT04627012","phase":"","title":"Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-01","conditions":"Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases","enrollment":600},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06195254","phase":"","title":"Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2020-12-01","conditions":"Stereotactic Body Radiotherapy, PD-1 Inhibitors, Pancreatic Cancer","enrollment":19},{"nctId":"NCT05273827","phase":"","title":"Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-03-22","conditions":"Immunotherapy, Analgesia, NSCLC","enrollment":81},{"nctId":"NCT06170710","phase":"PHASE2","title":"Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":173},{"nctId":"NCT06121700","phase":"PHASE2","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-01-01","conditions":"Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer","enrollment":55},{"nctId":"NCT06119347","phase":"","title":"Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs","enrollment":1581},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT06031376","phase":"","title":"Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2019-07-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":106},{"nctId":"NCT06011330","phase":"","title":"Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2019-01-01","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT04680598","phase":"","title":"Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-25","conditions":"Hepatocellular Carcinoma","enrollment":800},{"nctId":"NCT04975932","phase":"","title":"Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study","status":"COMPLETED","sponsor":"Zhongda Hospital","startDate":"2021-07-01","conditions":"Hepatocellular Carcinoma","enrollment":826},{"nctId":"NCT05942768","phase":"","title":"Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2019-07-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":103},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT05809336","phase":"PHASE2, PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":"Advanced Solid Tumor","enrollment":172},{"nctId":"NCT03732664","phase":"PHASE1","title":"ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-01","conditions":"High-Risk Resectable NSCLC","enrollment":27},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT05573282","phase":"","title":"Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-16","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05509478","phase":"PHASE2","title":"Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2022-08-20","conditions":"Biliary Tract Cancer","enrollment":46},{"nctId":"NCT05461235","phase":"PHASE2","title":"Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2022-07-15","conditions":"PD-1 Antibody, DC-Cell, NK-Cell","enrollment":1},{"nctId":"NCT05339581","phase":"NA","title":"IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-05-20","conditions":"Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma","enrollment":78},{"nctId":"NCT05322187","phase":"PHASE2, PHASE3","title":"Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-04-10","conditions":"Transitional Cell Tumor, Hepatoblastoma, Liver Cancer","enrollment":15},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT05008861","phase":"PHASE1","title":"Gut Microbiota Reconstruction for NSCLC Immunotherapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":"Gastric Cancer","enrollment":433},{"nctId":"NCT04639284","phase":"","title":"Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-12-23","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT04771715","phase":"","title":"Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-01","conditions":"Advanced Colorectal Carcinoma","enrollment":100},{"nctId":"NCT04252365","phase":"PHASE2","title":"Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2020-03-01","conditions":"Nsclc","enrollment":20},{"nctId":"NCT03966456","phase":"","title":"Real World Study of Four PD-1 Agents in China","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2018-06-01","conditions":"Thoracic Cancer, Gynecologic Cancer, Abdomen Tumors","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":134,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["time-of-day of administration of immunochemotherapy"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab, Sintilimab","genericName":"Pembrolizumab, Sintilimab","companyName":"Hunan Province Tumor Hospital","companyId":"hunan-province-tumor-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab and Sintilimab are PD-1 inhibitors that block the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby releasing the brakes on anti-tumor immune responses. Used for Non-small cell lung cancer, Melanoma, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}